We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

EKF Diagnostics Displays POC Analyzers for Hemoglobin, HbA1c And Lactate at MEDLAB Middle East

By LabMedica International staff writers
Posted on 05 Feb 2020
Illustration
Illustration
EKF Diagnostics (Cardiff, Wales, UK) showcased its full product range, including the Quo-Test A1c, Quo-Lab A1c, Hemo Control, DiaSpect Tm and Lactate Scout 4 analyzers, at MEDLAB Middle East, which took place from 3-6 February 2020 at the Dubai World Trade Centre. MEDLAB Middle East, the Middle East & North Africa (MENA) region’s largest medical laboratory exhibition and congress, drew over 25,800 medical laboratory industry professionals and 600 exhibitors from 35 countries.

EKF Diagnostics is a global medical manufacturer of point-of-care (POCT) devices and tests for hemoglobin, glycated hemoglobin (HbA1c), glucose and lactate. Its POC analyzers are designed for use within doctors' surgeries, clinics, hospitals and laboratories to provide fast and accurate results at an affordable price. EKF Central Laboratory division manufactures a wide spectrum of reagents for use in hospital laboratories across a broad portfolio of automated and semi-automated analyzers.

Among its Hemoglobin products on display at MEDLAB Middle East were the Hemo Control POC hemoglobin analyzer designed to provide quantitative, lab quality hemoglobin results from 25 seconds; DiaSpect Tm, the world’s fastest hemoglobin analyzer that delivers laboratory quality results in just about one second of the microcuvette being placed into the palm-sized analyzer; and the HemataStat II microhematocrit centrifuge that provides a quantitative hematocrit reading for up to six blood samples from one 60 second spin.

EKF Diagnostics’ Diabetes products on display at this year’s MEDLAB Middle East included the Quo-Lab HbA1c semi-automated desktop POC analyzer for measuring glycated hemoglobin (HbA1c); and the Quo-Test fully automated desktop POC analyzer designed for easy and reliable HbA1c measurement for the monitoring and management of diabetes in a POC setting such as diabetes clinics and doctors’ surgeries. In the Sports segment, EKF Diagnostics displayed the Lactate Scout 4 handheld analyzer that requires a very small blood sample to deliver lactate measurement in 10 seconds and is programmed with step-testing features designed to improve athletic performance over time.

Related Links:
EKF Diagnostics

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx

DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
PURITAN MEDICAL